ESSA Gross Profit vs Cost Of Revenue Analysis
EPIX Stock | USD 1.79 0.02 1.10% |
ESSA Pharma financial indicator trend analysis is much more than just examining ESSA Pharma latest accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ESSA Pharma is a good investment. Please check the relationship between ESSA Pharma Gross Profit and its Cost Of Revenue accounts. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.
Gross Profit vs Cost Of Revenue
Gross Profit vs Cost Of Revenue Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ESSA Pharma Gross Profit account and Cost Of Revenue. At this time, the significance of the direction appears to have pay attention.
The correlation between ESSA Pharma's Gross Profit and Cost Of Revenue is -0.89. Overlapping area represents the amount of variation of Gross Profit that can explain the historical movement of Cost Of Revenue in the same time period over historical financial statements of ESSA Pharma, assuming nothing else is changed. The correlation between historical values of ESSA Pharma's Gross Profit and Cost Of Revenue is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Gross Profit of ESSA Pharma are associated (or correlated) with its Cost Of Revenue. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cost Of Revenue has no effect on the direction of Gross Profit i.e., ESSA Pharma's Gross Profit and Cost Of Revenue go up and down completely randomly.
Correlation Coefficient | -0.89 |
Relationship Direction | Negative |
Relationship Strength | Significant |
Gross Profit
Gross profit is a required income statement account that reflects total revenue of ESSA Pharma minus its cost of goods sold. It is profit before ESSA Pharma operating expenses, interest payments and taxes. Gross profit is also known as gross margin. The profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services.Cost Of Revenue
Cost of Revenue is found on ESSA Pharma income statement and represents the costs associated with goods and services ESSA Pharma provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.Most indicators from ESSA Pharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ESSA Pharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ESSA Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more information on how to buy ESSA Stock please use our How to Invest in ESSA Pharma guide.Selling General Administrative is likely to drop to about 7.5 M in 2024. Tax Provision is likely to drop to 1,368 in 2024
ESSA Pharma fundamental ratios Correlations
Click cells to compare fundamentals
ESSA Pharma Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ESSA Pharma fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 80.6M | 198.2M | 169.5M | 149.1M | 171.5M | 180.1M | |
Other Current Liab | 24.2M | 39.2M | 36.4M | 1.4M | 1.6M | 1.5M | |
Total Current Liabilities | 1.2M | 3.9M | 2.3M | 3.5M | 4.0M | 3.0M | |
Total Stockholder Equity | 79.2M | 194.0M | 167.1M | 145.6M | 167.5M | 175.8M | |
Net Debt | (56.3M) | (137.5M) | (56.9M) | (33.6M) | (30.3M) | (31.8M) | |
Retained Earnings | (81.0M) | (117.8M) | (152.9M) | (179.5M) | (161.5M) | (153.4M) | |
Accounts Payable | 678.6K | 1.4M | 954.6K | 2.0M | 2.3M | 1.4M | |
Cash | 56.3M | 137.8M | 57.1M | 33.7M | 38.8M | 34.1M | |
Non Current Assets Total | 55.2K | 567.7K | 446.0K | 325.3K | 374.0K | 383.8K | |
Non Currrent Assets Other | (200.7K) | 277.6K | 259.5K | 257.2K | 295.8K | 181.3K | |
Cash And Short Term Investments | 56.3M | 194.9M | 57.1M | 148.1M | 170.3M | 178.8M | |
Other Current Assets | 1.7M | 2.2M | 1.8M | 585.4K | 673.2K | 1.2M | |
Other Stockholder Equity | 31.2M | 36.4M | 44.0M | 49.0M | 56.4M | 59.2M | |
Total Liab | 1.3M | 4.2M | 2.4M | 3.5M | 4.0M | 4.6M | |
Total Current Assets | 80.6M | 197.6M | 169.5M | 148.8M | 171.1M | 179.7M | |
Common Stock | 131.1M | 277.4M | 278.1M | 278.2M | 319.9M | 335.9M | |
Other Liab | 19.6K | 16.5K | 127.4K | 20.4K | 18.3K | 17.4K | |
Net Tangible Assets | 49.0M | 79.2M | 194.0M | 167.1M | 192.2M | 201.8M | |
Other Assets | (55.2K) | 198.2M | (446.0K) | 115.4M | 132.7M | 139.3M | |
Net Receivables | 309.5K | 489.0K | 6.2K | 135.1K | 121.6K | 115.5K | |
Liabilities And Stockholders Equity | 80.6M | 198.2M | 169.5M | 149.1M | 171.5M | 180.1M | |
Inventory | 420.5K | (360.8K) | (309.5K) | 110.6M | 127.2M | 133.6M | |
Short Term Debt | 59.1K | 120.7K | 133.8K | 80.3K | 92.4K | 87.8K | |
Common Stock Shares Outstanding | 22.4M | 38.5M | 44.0M | 44.1M | 50.7M | 53.2M | |
Non Current Liabilities Total | 127K | 230.6K | 77K | (71.0) | (63.9) | (60.7) | |
Short Long Term Debt Total | 59.1K | 331.0K | 209.8K | 80.3K | 72.3K | 68.7K | |
Net Invested Capital | 79.2M | 194.0M | 167.1M | 145.6M | 167.5M | 103.4M | |
Net Working Capital | 79.1M | 193.7M | 166.7M | 145.3M | 167.1M | 101.6M | |
Capital Stock | 131.1M | 277.4M | 278.1M | 278.2M | 319.9M | 198.2M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for ESSA Stock Analysis
When running ESSA Pharma's price analysis, check to measure ESSA Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ESSA Pharma is operating at the current time. Most of ESSA Pharma's value examination focuses on studying past and present price action to predict the probability of ESSA Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ESSA Pharma's price. Additionally, you may evaluate how the addition of ESSA Pharma to your portfolios can decrease your overall portfolio volatility.